A team of Wistar researchers led by Hildegund C.J. Ertl—a professor in The Wistar Institute’s Vaccine & Immunotherapy Center—has demonstrated that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors. The study was published in Molecular Therapy Oncolytics.
The Fund for Science and Technology announced an inaugural suite of grants and its plan to fund at least $500 million over the next four years to support transformational science and technology for people and the planet.
